{"id":"topical-timolol-maleate-0-5-eye-drops","safety":{"commonSideEffects":[{"rate":null,"effect":"Ocular irritation or discomfort"},{"rate":null,"effect":"Blurred vision"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Systemic beta-blockade effects (bradycardia, bronchospasm in susceptible patients)"}]},"_chembl":{"chemblId":"CHEMBL1200870","moleculeType":"Small molecule","molecularWeight":"432.50"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Timolol blocks beta-1 and beta-2 adrenergic receptors on the ciliary body epithelium, which reduces the rate of aqueous humor secretion. This leads to a decrease in intraocular pressure, making it effective for treating glaucoma and ocular hypertension. The 0.5% topical formulation is applied directly to the eye for local therapeutic effect.","oneSentence":"Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:13:17.410Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT07474883","phase":"EARLY_PHASE1","title":"Efficacy of 0.5% Topical Timolol Eye Drops in the Treatment of Post-Inflammatory Erythema Following Acne Vulgaris","status":"NOT_YET_RECRUITING","sponsor":"Pham Ngoc Thach University of Medicine","startDate":"2026-03-09","conditions":"Post Inflammtory Erythema, Acne Vulgaris, Erythema","enrollment":60},{"nctId":"NCT05479123","phase":"PHASE4","title":"Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas","status":"TERMINATED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2022-06-23","conditions":"Infantile Hemangioma","enrollment":52},{"nctId":"NCT07384767","phase":"PHASE2","title":"Efficacy and Safety of Topical Timolol in Secondary Intention Surgical Wounds Healing","status":"NOT_YET_RECRUITING","sponsor":"University of California, Davis","startDate":"2026-06-01","conditions":"Mohs Micrographic Surgery, Excision Margin","enrollment":220},{"nctId":"NCT07168902","phase":"PHASE2","title":"Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension","status":"RECRUITING","sponsor":"Bausch & Lomb Incorporated","startDate":"2025-10-24","conditions":"Glaucoma","enrollment":228},{"nctId":"NCT06643416","phase":"PHASE3","title":"Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia","status":"RECRUITING","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2024-10-09","conditions":"Paronychia, EGFR-TKI, ALK-TKI","enrollment":40},{"nctId":"NCT06140186","phase":"PHASE3","title":"Efficacy and Safety of Timolol for TKI Induced Paronychia","status":"UNKNOWN","sponsor":"Queen Mary Hospital, Hong Kong","startDate":"2023-04-01","conditions":"Paronychia","enrollment":40},{"nctId":"NCT06152861","phase":"PHASE2","title":"Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension","status":"UNKNOWN","sponsor":"Glaukos Corporation","startDate":"2023-11-15","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":250},{"nctId":"NCT01873131","phase":"NA","title":"A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2011-02","conditions":"Hemangioma","enrollment":126},{"nctId":"NCT01685398","phase":"PHASE3","title":"Topical Timolol for Superficial Infantile Hemangioma","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2012-09","conditions":"Hemangioma","enrollment":48},{"nctId":"NCT03691649","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-14","conditions":"Glaucoma and Ocular Hypertension","enrollment":426},{"nctId":"NCT03691662","phase":"PHASE3","title":"A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2018-09-27","conditions":"Glaucoma and Ocular Hypertension","enrollment":417},{"nctId":"NCT05165082","phase":"NA","title":"The Efficacy of Topical Timolol Combined With Cryotherapy in EGFR Inhibitors-induced Paronychia - a Double-blinded, Intrapatient Left-to-right Controlled Study","status":"COMPLETED","sponsor":"Taipei Medical University WanFang Hospital","startDate":"2021-12-21","conditions":"Paronychia, Epidermal Growth Factor Receptor Inhibitor","enrollment":8},{"nctId":"NCT03284853","phase":"PHASE3","title":"Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2017-09-05","conditions":"Open Angle Glaucoma, Ocular Hypertension","enrollment":436},{"nctId":"NCT03648229","phase":"PHASE4","title":"African Glaucoma Laser Trial","status":"WITHDRAWN","sponsor":"West Virginia University","startDate":"2019-09-01","conditions":"Open-angle Glaucoma","enrollment":""},{"nctId":"NCT04288700","phase":"PHASE4","title":"Evaluation of the Efficacy of Captopril Versus Propranolol and Timolol as a Treatment of Infantile Capillary Hemangioma","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2019-10-01","conditions":"Infantile Hemangioma","enrollment":100},{"nctId":"NCT03966365","phase":"PHASE1","title":"Safety and Tolerability of the Preservative-free Ophthalmic Solution PRO-122 Compared With Krytantek Ofteno®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-05-02","conditions":"Glaucoma","enrollment":24},{"nctId":"NCT01257698","phase":"NA","title":"Effect of Topical Aqueous Suppressants on Intraocular Gas Duration Following Pars Plana Vitrectomy","status":"COMPLETED","sponsor":"Mid Atlantic Retina","startDate":"2010-02","conditions":"Macular Hole, Retinal Detachment","enrollment":21},{"nctId":"NCT01749930","phase":"PHASE3","title":"Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01749904","phase":"PHASE3","title":"Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2013-01-31","conditions":"Open-Angle Glaucoma, Ocular Hypertension","enrollment":420},{"nctId":"NCT01707381","phase":"PHASE2","title":"BOL-303259-X With Timolol 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2012-11","conditions":"Ocular Hypertension, Open Angle Glaucoma","enrollment":25},{"nctId":"NCT01843920","phase":"NA","title":"The Effect of Glaucoma Drops on of the Duration of a Pure Intraocular Gas Bubble","status":"COMPLETED","sponsor":"Jason Hsu, MD","startDate":"2011-06","conditions":"Scleral Buckling","enrollment":21},{"nctId":"NCT01927406","phase":"PHASE4","title":"The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2014-06","conditions":"Thyroid Eye Disease, Ocular Hypertension, Glaucoma","enrollment":""},{"nctId":"NCT01915940","phase":"PHASE2","title":"Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"ForSight Vision5, Inc.","startDate":"2013-10-23","conditions":"Primary Open-Angle Glaucoma, Ocular Hypertension","enrollment":169},{"nctId":"NCT01535768","phase":"PHASE4","title":"Effect of Prophylactic Aqueous Suppression on Hyperencapsulation of Ahmed Glaucoma Valves","status":"UNKNOWN","sponsor":"Credit Valley EyeCare","startDate":"2012-02","conditions":"Glaucoma","enrollment":150},{"nctId":"NCT01434849","phase":"PHASE1","title":"Timolol for the Prevention of Proliferation of Infantile Hemangioma (TiPPIH Trial)","status":"TERMINATED","sponsor":"Alice K. Gong","startDate":"2012-07","conditions":"Infantile Hemangioma, Very Low Birth Weight Infants","enrollment":26},{"nctId":"NCT02214680","phase":"PHASE2","title":"The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter","status":"UNKNOWN","sponsor":"Carmel Medical Center","startDate":"2015-10","conditions":"Healthy","enrollment":25},{"nctId":"NCT00275756","phase":"NA","title":"Effects of Common Topical Glaucoma Therapy on Optic Nerve Head Blood Flow Autoregulation During Increased Arterial Blood Pressure and Artificially Elevated Intraocular Pressure in Healthy Humans","status":"WITHDRAWN","sponsor":"Medical University of Vienna","startDate":"2008-09","conditions":"Glaucoma","enrollment":""},{"nctId":"NCT01263444","phase":"PHASE4","title":"Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-03","conditions":"Glaucoma, Ocular Hypertension","enrollment":47},{"nctId":"NCT01327599","phase":"PHASE4","title":"Efficacy of Changing to DUOTRAV® From Prior Therapy","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2011-08","conditions":"Open-Angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma","enrollment":60},{"nctId":"NCT01514734","phase":"PHASE4","title":"Assessing the Efficacy and Tolerability of AZARGA® (Brinzolamide 1%/Timolol 0.5% Fixed Combination) as Replacement Therapy in Patients on COMBIGAN® (Brimonidine 0.2%/Timolol 0.5% Fixed Combination) Therapy in Brazil","status":"TERMINATED","sponsor":"Alcon Research","startDate":"2012-03","conditions":"Glaucoma","enrollment":9},{"nctId":"NCT00800423","phase":"PHASE3","title":"Effect of Topical Brimonidine on Post Cataract Surgery Corneal Edema","status":"UNKNOWN","sponsor":"Rabin Medical Center","startDate":"2009-01","conditions":"Corneal Edema, Visual Acuity","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"topical Timolol maleate 0.5% eye drops","genericName":"topical Timolol maleate 0.5% eye drops","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Timolol maleate is a non-selective beta-adrenergic receptor antagonist that reduces intraocular pressure by decreasing aqueous humor production in the eye. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}